UNSPSC 51372800: Controlled substanceanalgesic azocines

Controlled substance analgesic drugs made from single-ringed, eight-membered, compounds bearing seven carbon atoms, a nitrogen atom, and four double bonds.

UNSPSC 51372800 Controlled substance analgesic azocines, a Class code, encompasses pharmaceutical procurement by state and local governments focused on opioid antagonists, overdose-reversal medications, and related controlled-substance therapeutics. Based on recent solicitations, state and local buyers are acquiring naloxone (an opioid antagonist), safe drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products through both direct procurements and cooperative purchasing arrangements. Issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). The procurement model varies—some jurisdictions conduct direct competitive bidding for specific volumes, while state-level entities use RFPs and RFIs to establish master contracts distributed through authorized wholesalers or to gather market intelligence on direct-to-manufacturer contracting models.

Geographic activity is concentrated in the Southeast (Florida) and Upper Midwest (Minnesota, with multistate reach), with Texas representing emerging activity in pharmacy benefit program redesign. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually (due July 26, 2023, with quarterly deliveries to a county health building), the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs (posted April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products open to manufacturers through three authorized wholesalers with responses due March 26, 2026, and contract effectiveness July 1, 2026. Winning vendors must meet DEA compliance, cGMP certification, Drug Supply Chain Security Act requirements, and E-Verify eligibility; cooperative purchasing contracts typically carry administrative fee structures (3 percent in MMCAP's case) and performance penalties for reporting or onboarding delays.